SYNTHESIS OF DEUTERIUM AND TRITIUM LABELLED 7-HYDROXY- AND

7-OXOSTEROLS

H. Schabdach, J. Schröder, K. Seifert

University of Bayreuth, Organic Chemistry I/2, NW II, D-95440 Bayreuth, Germany

SUMMARY

Deuterium and tritium 3,7-bis-labelled 7-hydroxysterols 3 - 5 were prepared by reduction of the 3,7-

dioxosterols 1, 2 with NaB2H4 and NaB3H4. Regioselective oxidation of the deuterium 3,7-bis-

labelled 7-hydroxysterols 3, 4 with CrO₃/DMP led to the 3-labelled 7-oxosterols 6, 7. The 3,7-

dioxosterols 1, 2 were synthesized starting from cholesterol and β-sitosterol.

Key words: 7-Hydroxysterols, 7-oxosterols, specific labelling, deuterium, tritium, plant disease

resistance inducing compounds

INTRODUCTION

The 7 β -hydroxysterols stigmast-5-ene-3 β ,7 β -diol, cholest-5-ene-3 β ,7 β -diol, the 7 α -hydroxysterols

stigmast-5-ene-3 β ,7 α -diol, cholest-5-ene-3 β ,7 α -diol and the 7-oxosterols 3 β -hydroxystigmast-5-en-

7-one, 3B-hydroxycholest-5-en-7-one induce resistance toward the fungal pathogens Puccinia

striiformis West. and Puccinia hordei Otth in barley and wheat [1]. Since we were interested in the

investigation of the uptake, translocation and metabolism of 3 - 7 in barley and wheat, the

compounds were regioselectively labelled in positions 3 and 7 with deuterium and tritium.

Cholest-5-ene-3ß,7ß-diol shows significant cytotoxic activity toward tumor cells [2, 3] as well as

inhibition of the HMG-CoA-reductase activity [4]. So specific double labelling (deuterium, tritium)

of this compound is also of interest in the field of pharmacological and biochemical investigations.

CCC 0362-4803/98/040329-08\$17.50 ©1998 John Wiley & Sons, Ltd.

Received 31 October 1997 Revised 10 December 1997

SYNTHESIS

The 3,7-dioxosterols 1, 2 were reduced with NaB²H₄ and NaB³H₄ in THF/MeOH to the deuterium and tritium labelled 7β-hydroxysterols 3 - 5 in a yield of 87 - 90% besides approximately 5% of the epimeric 7α-hydroxysterols, separated by TLC or column chromatography (CC) on silica gel. The specific radioactivity of [3α,7α-³H₂]-stigmast-5-ene-3β,7β-diol (5) was 193 MBq/mmol. The introduction of deuterium in position 3/7 followed from the lack of the ¹³C-NMR signals for C-3 (8 71.4) / C-7 (8 73.3) in a proton broad band-decoupled ¹³C-NMR spectrum and the ¹H-NMR signals for H-3α (8 3.52) / H-7α (8 3.82, 3, 8 3.83, 4). The allylic oxidation of the ²H-labelled 7-hydroxysterols 3, 4 with CrO₃/DMP (3,5-dimethylpyrazole) [5] gave the 7-oxosterols 6, 7. [3α,4β,7β-²H₃]-Cholest-5-ene-3β,7α-diol was previously prepared from cholest-4-en-3-one by equilibration in tert.-BuOH and tert.-BuOK followed by addition of [1-²H]-acetic acid and reduction with NaB²H₄. The formed [3α,4β-²H₂]-cholest-5-en-3β-ol was oxidized with chromic acid to [3α,4β-²H₂]-3β-hydroxycholest-5-en-7-one reduced with LiAl²H₄ to [3α,4β,7β-²H₃]-cholest-5-ene-3β,7α-diol [6].

 $1 R^1 = H$

3 $R^1 = H R^2 = {}^2H$ (90%)

 $2 R^1 = Et$

- 4 $R^1 = Et R^2 = {}^2H$ (87%)
- 5 $R^1 = Et R^2 = {}^3H$ (90%)

- 6 $R^1 = H R^2 = {}^2H$ (63%)
- 7 $R^1 = Et R^2 = {}^2H$ (64%)

The preparation of cholest-5-ene-3,7-dione (1) by Jones oxidation of cholest-5-ene-3β,7β-diol (without information on the yield) is described by Shoppee and Newman [7]. In our hands the Jones oxidation of 3β-hydroxycholest-5-en-7-one gave 1 in a yield of only 20%. The oxidation of cholest-3,5-dien-7-one with performic acid gave a mixture of cholest-5-ene-3,7-dione (1), 3α,4α-epoxycholest-5-en-7-one, 3α,4β-dihydroxycholest-5-en-7-one and 3α-formyloxy-4β-hydroxycholest-5-en-7-one [8]. So the 3,7-dioxosterols 1, 2 were synthesized in the following way. Cholesterol and β-sitosterol were oxidized with PCC (pyridinium chlorochromate) to cholest-4-en-3-one (8) and stigmast-4-en-3-one (9). Ketalization of the 3-oxo-group of 8, 9 with ethylene glycol in the presence of PPTS [pyridinium p-toluenesulphonate] led in nearly quantitative yields to 10, 11 which were oxidized with CrO₃/DMP to 12, 13. The ketals were hydrolyzed with LiBF₄/H₂O/MeCN

[9] to the 3,7-dioxosterols 1, 2. The assignments of the ¹H- and ¹³C-NMR data for the sterols were based on ¹H-, ¹H ¹H COSY-, ¹³C-, ¹³C APT-, and ¹H ¹³C COSY-experiments.

According to UV measurements in CHCl₃ [7] and EtOH [10] cholest-5-ene-3,7-dione (1) was described as 3-hydroxycholest-3,5-dien-7-one. The ¹³C-NMR spectrum of 1 in CDCl₃ shows 2 CO signals at δ 206.3 (C-3) and 198.3 (C-7). So the 3,7-dioxosterol 1 can not exist in the enol form.

EXPERIMENTAL

$[3\alpha,7\alpha^{-3}H_2]$ -Stigmast-5-ene-3 β ,7 β -diol (5)

32.0 mg (0.075 mmol) of stigmast-5-ene-3,7-dione (2), dissolved in 1.2 ml of THF/MeOH (2:1) was added to 1.4 mg (0.037 mmol, 51 MBq) of NaB³H₄ and stirred for 1 hr at room temperature. The reaction was stopped by addition of 500 µl of 3% hydrochloric acid. After 15 min 1.2 ml of CH₂Cl₂ was added and the mixture stirred for 45 min. The organic phase was separated and evaporated under reduced pressure to dryness. Preparative TLC (cyclohexane/EtOAc (1:1)) of the residue yielded 29 mg (90%) of 5 with a specific radioactivity of 193 MBq/mmol. The ³H-labelled sterol 5 showed identical chromatographic behaviour with the authentic non-labelled compound

$[3\alpha,7\alpha^{-2}H_2]$ -Cholest-5-ene-3 β ,7 β -diol (3), $[3\alpha,7\alpha^{-2}H_2]$ -stigmast-5-en-3 β ,7 β -diol (4)

80 mg (0.20 mmol) of cholest-5-ene-3,7-dione (1) and 42 mg (1.0 mmol) of NaB²H₄ were added to 10 ml of a 0.4 M solution of CeCl₃ 7 H₂O in THF/MeOH (2:1). The mixture was stirred for 1 hr at room temperature. The reaction was stopped by addition of 10 ml of H₂O and 30 ml of Et₂O. The organic phase was separated, dried with Na₂SO₄ and evaporated. Column chromatography of the residue on 30 g of silica gel with cyclohexane/EtOAc (1:1) yielded 73 mg (90%) of 3. R_f 0.28, cyclohexane/EtOAc (1:1). m. p. 174 - 175°C. MS 70 eV m/z (rel. int.): 386 (M⁺-H₂O, 100). ¹H-NMR: δ 5.27 (d, J = 1.4, H-6), 0.67 (s, 3H-18), 1.05 (s, 3H-19), 0.99 (d, J = 6.9, 3H-21), 0.85 (d, J = 6.5, 3H-26, 3H-27).

The same procedure was used for the preparation of 4. The reduction of 70 mg (0.16 mmol) of 2 gave 62 mg (87%) of 4. R_f 0.28, cyclohexane/EtOAc (1:1). m. p. 169-171°C. MS 70 eV m/z (rel.

int.): 414 (M⁺-H₂O, 100), 285 (15), 190 (20). ¹H-NMR: δ 5.26 (d, J = 1.4, H-6), 0.67 (s, 3H-18), 1.03 (s, 3H-19), 0.90 (d, J = 6.5, 3H-21), 0.79 (d, J = 6.6, 3H-26*), 0.81 (d, J = 6.6, 3H-27*), 0.82 (m, 3H-29).

$[3\alpha^{-2}H]$ -3\beta-Hydroxycholest-5-en-7-one (6), $[3\alpha^{-2}H]$ -3\beta-hydroxystigmast-5-en-7-one (7)

50 mg (0.50 mmol) of CrO₃ (dried with P_4O_{10}) was suspended in 3 ml of anhydrous CH_2Cl_2 at -20°C under nitrogen and 48 mg (0.50 mmol) of DMP was added. The resulting mixture was stirred for 15 min at -20°C. 35 mg (0.087 mmol) of $[3\alpha,7\alpha^{-2}H_2]$ -cholest-5-ene-3 β ,7 β -diol (3) was added and the reaction mixture stirred for 1h maintaining a temperature between -10 and -20°C. 30 ml of CH_2Cl_2 and 5 ml of 5% hydrochloric acid were added, the organic phase was separated, dried with Na_2SO_4 and evaporated. Column chromatography of the residue on 10 g of silica gel with cyclohexane/EtOAc (1:1) gave 22 mg (63%) of 6. R_f 0.36, cyclohexane/EtOAc (1:1). m. p. 169-170°C. MS 70 eV m/z (rel. int.): 401 (M⁺, 100), 368 (18), 288 (10), 193 (12). ¹H-NMR: δ 5.65 (d, J = 1.5, H-6), 2.24 (dd, J = 11.6, H-8), 0.64 (s, 3H-18), 1.16 (s, 3H-19), 0.89 (d, J = 6.5, 3H-21), 0.83 (d, J = 6.6, 3H-26, 3H-27).

Starting from 30 mg (0.069 mmol) of 4 19 mg (64%) of 7 was obtained. R_f 0.37, cyclohexane/EtOAc (1:1). m. p. 149-150°C. MS 70 eV m/z (rel. int.): 429 (M⁺, 100), 396 (10), 288(10), 193(20). ¹H-NMR: δ 5.65 (d, J = 1.5, H-6), 2.21 (dd, J = 11.0, H-8), 0.66 (s, 3H-18), 1.17 (s, 3H-19), 0.90 (d, J = 6.5, 3H-21), 0.78 (d, J = 6.6, 3H-26*), 0.80 (d, J = 6.6, 3H-27*), 0.83 (m, 3H-29).

Cholest-4-en-3-one (8), stigmast-4-en-3-one (9)

1.55 g (4.0 mmol) of cholesterol and 21.6 g (100 mmol) of PCC were dissolved in 70 ml of benzene and refluxed for 4h. 100 ml of Et₂O was added and the mixture filtered. The organic phase was treated with saturated NaCl-solution, dried with Na₂SO₄ and evaporated. The residue was chromatographed on 70 g of silica gel with cyclohexane/EtOAc (2:1) and yielded 1.31 g (85%) of 8. R_f 0.49 cyclohexane/EtOAc (3:1). m. p. 89-91°C ([11] m. p. 80-81.5°C) MS 70 eV m/z (rel. int.):

384 (M⁺, 20), 271 (10), 242 (30), 124 (100). ¹H-NMR: δ 5.69, (d, J = 1.1, H-4), 0.68 (s, 3H-18), 1.15 (s, 3H-19), 0.88 (d, J = 6.5, 3H-21), 0.84 (d, J = 6.6, 3H-26, 3H-27).

The same procedure starting from 1.66 g (4.0 mmol) of β -sitosterol gave 1.32 g (80%) of 9. R_f 0.49 cyclohexane/EtOAc (3:1). m. p. 94-95°C ([12] m. p. 95-96.5°C). MS 70 eV m/z (rel. int.): 412 (M⁺, 10), 370 (30), 289 (35), 229 (50) 124 (100). ¹H-NMR: δ 5.68 (d, J = 1.5, H-4), 0.68 (s, 3H-18), 1.14 (s, 3H-19), 0.88 (d, J = 6.5, 3H-21), 0.80 (d, J = 6.5, 3H-26*), 0.79 (d, J = 6.5, 3H-27*), 0.81 (m, 3H-29).

3,3-Ethylenedioxycholest-5-ene (10), 3,3-ethylenedioxystigmast-5-ene (11)

1.20 g (3.1 mmol) of cholest-4-en-3-one (8), 1 ml (18 mmol) of ethylene glycol and 150 mg (0.6 mmol) of PPTS were dissolved in 50 ml of benzene and refluxed for 12 h by means of a Dean - Stark trap. Benzene was evaporated, the residue dissolved in CH_2Cl_2 and washed with water. The organic phase was dried with Na_2SO_4 , evaporated and yielded 1.30 g (97%) of 10. R_f 0.55 cyclohexane/EtOAc (7:1). m. p. 131-132°C ([13] m. p. 134-135 °C). ¹H-NMR: δ 2.08 (dd, J = 14.2, J = 2.7, H-4), 2.54 (m, H-4), 5.32 (m, H-6), 0.65 (s, 3H-18), 0.99 (s, 3H-19), 0.88 (d, J = 6.5, 3H-21), 0.83 (d, J = 6.6, 3H-26, 3H-27), 3.91 (m, 2H-1', 2H-2').

Starting from 1.25 g (3.0 mmol) of 9 1.32 g (95%) of 11 was obtained. R_f 0.55 cyclohexane/EtOAc (7:1). m. p. 135-137°C. ¹H-NMR: δ 2.07 (dd, J = 14.2, J = 2.8, H-4), 2.53 (m, H-4), 5.32 (m, H-6), 0.65 (s, 3H-18), 0.99 (s, 3H-19), 0.90 (d, J = 6.5, 3H-21), 0.80 (d, J = 6.5, 3H-26*), 0.82 (d, J = 6.5, 3H-27*), 0.81 (m, 3H-29), 3.90 (m, 2H-1', 2H-2').

3,3-Ethylenedioxycholest-5-en-7-one (12), 3,3-ethylenedioxystigmast-5-en-7-one (13)

2.80 g (28 mmol) of CrO₃ (dried with P₄O₁₀) was suspended in 40 ml of anhydrous CH₂Cl₂ at -20°C under nitrogen and 2.69 g (28.0 mmol) DMP was added. The mixture was stirred for 20 min maintaining a temperature between -10 and -20°C. 1.20 g (2.8 mmol) of 3,3-ethylenedioxycholest-5-ene (10) was added and the mixture stirred for 5 h at -20°C. 100 ml of CH₂Cl₂ and 30 ml of 5% hydrochloric acid were added. The organic phase was separated, dried with Na₂SO₄ and evaporated.

The chromatography of the residue on 130 g of silica gel with cyclohexane/EtOAc (3:1) gave 806 mg (64%) of 12. R_f 0.32 cyclohexane/EtOAc (7:1). m. p. 147-148°C ([14] m. p. 146-147.5°C) MS 70 eV m/z (rel. int.): 442 (M $^+$, 10), 99 (100). 1 H-NMR: δ 2.28 (dd, J = 14.8, J = 2.8, H-4), 2.63 (dd, J = 14.8, J = 1.8, H-4), 5.62 (d, J = 1.8, H-6), 2.18 (dd, J = 10.9, H-8), 0.64 (s, 3H-18), 1.16 (s, 3H-19), 0.88 (d, J = 6.4, 3H-21), 0.82 (d, J = 6.5, 3H-26, 3H-27), 3.92 (m, 2H-1', 2H-2'). Starting from 1.20 g (2.6 mmol) of 11 832 mg (67%) of 13 were obtained. R_f 0.32 cyclohexane/EtOAc (7:1). m. p. 137-139°C. MS 70 eV m/z (rel. int.): 470 (M $^+$, 10), 99 (100). 1 H-NMR δ 2.26 (dd, J = 14.7, J = 2.9, H-4), 2.62 (dd, J = 14.7, J = 1.8, H-4), 5.61 (d, J = 1.8, H-6), 2.18 (dd, J = 10.6, H-8), 0.64 (s, 3H-18), 1.16 (s, 3H-19), 0.88 (d, J = 6.5, 3H-21), 0.78 (d, J = 6.7, 3H-26*), 0.80 (d, J = 6.7, 3H-27*), 0.81 (m, 3H-29), 3.91 (m, 2H-1', 2H-2').

Cholest-5-ene-3,7-dione (1), stigmast-5-ene-3,7-dione (2)

100 mg (0.23 mmol) of 12, 94 mg (1.00 mmol) of LiBF₄, 0.5 ml of H₂O and 10 ml of MeCN were stirred for 24 h at 50°C. 10 ml of H₂O was added and the aqueous phase was extracted 2 x with 60 ml of CH₂Cl₂. The CH₂Cl₂ phase was dried with Na₂SO₄, evaporated and the residue chromatographed on 20 g of silica gel with cyclohexane/EtOAc (1:1). 74 mg (82%) of 1 was obtained. R_f 0.24 cyclohexane/EtOAc (3:1). m. p. 185-187°C ([7] m. p. 185°C). MS 70 eV m/z (rel. int.): 398 (M⁺, 100), 285 (20), 190 (35). 1 H-NMR: δ 3.02 (d, J = 15.1, H-4), 3.44 (dd, J = 15.1, J = 2.3, H-4), 5.68 (d, J = 2.3, H-6), 2.55 (dd, J = 11.6, H-8), 0.68 (s, 3H-18), 1.39 (s, 3H-19), 0.89 (d, J = 6.5, 3H-21), 0.83 (d, J = 6.6, 3H-26, 3H-27).

100 mg (0.21 mmol) of 13 was hydrolyzed in the same way to 72 mg (79%) of 2. R_f 0.24 cyclohexane/EtOAc (3:1). m. p. 165 -166°C. MS 70 eV m/z (rel. int.): 426 (M⁺, 100), 285 (15), 190 (20). ¹H-NMR: δ 3.00 (d, J = 15.0, H-4), 3.44 (dd, J = 15.0, J = 2.4, H-4), 5.67 (d, J = 2.4, H-6), 2.54 (dd, J = 11.6, H-8), 0.67 (s, 3H-18), 1.38 (s, 3H-19), 0.89 (d, J = 6.4, 3H-21), 0.77 (d, J = 6.5, 3H-26*), 0.79 (d, J = 6.5, 3H-27*), 0.80 (m, 3H-29).

* Assignments may be reversed.

REFERENCES

- 1. Schabdach, H., Johne, S., Steiner, U. and Seifert, K. Z. Naturforsch. 50c: 257-262 (1995)
- 2. Hietter, H., Bischoff, P, Beck, J.-P., Ourisson, G. and Luu B. Cancer Biochem. Biophys. 9: 75-83 (1986)
- 3. Hietter, H., Trifilieff, E., Richert, L., Beck, J.-P., Luu, B. and Ourisson, G. Biochem. Biophys. Res. Commun. 120: 657-664 (1984)
- Zander, M., Koch, P., Luu, B., Ourisson, G. and Beck, J.-P. J. Chem. Res., S, 219, M, 2572-2584 (1977)
- 5. Salmond, W. G., Barta, M. A. and Havens, J. L. J. Org. Chem. 43: 2057-2059 (1978)
- 6. Björkhem, I. and Kallner, A. J. Lipid Res. 17: 360-365 (1976)
- 7. Shoppee, C. W. and Newman, B. C. J. Chem. Soc. C 981-983 (1968)
- 8. Ahmad, M. S., Mushfiq, M. and Khan, N. Z. Indian J. Chem. 14B: 936-938 (1976)
- 9. Lipshutz, D. H. and Harvey, D. F. Synth. Commun. 12: 267-277 (1982)
- 10.Barnett, J., Ryman, B. E. and Smith, F. J. Chem. Soc. 526 528 (1946)
- 11. Manley, R. P., Curry, K. W., Deno, N. C. and Meyer, M. D. J. Org. Chem. 45: 4385-4387 (1980)
- 12. Lavie, D. and Kaye, I. A. J. Chem. Soc. 5001-5002 (1963)
- 13. Antonucci, R., Bernstein, S., Littele, R., Sax, K. J. and Williams, J. H. J. Org. Chem. 17: 1341-1350 (1952)
- 14. Huang, W.-H. and Huang, M. Hua Hsüeh Pao 24: 431-435 (1958); CA 54: 3502 g (1960)

Acknowledgements - This work was supported by the Deutsche Forschungsgemeinschaft (grant Se 595/2-1 and 2-2). We thank the DFG.